AQST News and Press, Aquestive Therapeutics Inc. From 05/04/22

Aquestive Therapeutics, Inc. (AQST) Q1 2022 Results Conference Call May 04, 2022 08:00 AM ET Company Participants Bennett Watson - Investor Relations Keith Kendall - Chief Executive Officer Ernie Toth - Chief Financial Officer Daniel Barber - Chief Operating Officer Conference Call Participan...

Aquestive Therapeutics press release (NASDAQ:AQST): Q1 GAAP EPS of -$0.32 beats by $0.09. Revenue of $12.27M (+10.3% Y/Y) beats by $2.15M. Cash and cash equivalents of $14.7M as of March 31, 2022 vs $28M as of Dec. 31, 2021. Reconfirming FY 2022 financial outlook. Company expects total r...

FDA continues to consider orphan drug exclusivity issues regarding Libervant's NDA Common stock purchase agreement secured for up to $40 million Part 3 of EPIPHAST trial for AQST-109 commenced in April and on track to report topline data in second quarter 2022 Hosts investment...

Sonoma Pharmaceuticals SNOA +47% on EPA approval of Nanocyn as hospital-grade disinfectant. Field Trip Health (FTRP) +23%. Harbor Custom Development (HCDI) +18%. Western Digital WDC +12% as activist Elliott calls for separation of flash business. AST SpaceMobile ASTS ...

WARREN, N.J., April 18, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, announced today that it will repo...

Provides Access to Additional Capital to Support Growth WARREN, N.J., April 13, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide tran...

Aquestive Therapeutics (NASDAQ:AQST) reported data from Part 2 of its EPIPHAST study of epinephrine oral film AQST-109 being explored for treating severe allergies, including anaphylaxis. The company said Part 2 of the EPIPHAST study was a replicate design crossover study in 24 heal...

AQST-109 is the first and only orally delivered epinephrine product candidate in clinical development Rapid absorption with a median time to peak concentration (Tmax) of 15 minutes confirmed in a larger subject population Study continues to show AQST-109 is s...

Summer Infant (SUMR) +29% on Q4 results. Imperial Petroleum (IMPP) +19%. Mullen Automotive (MULN) +19% featured by Yahoo Finance live. Indonesia Energy (INDO) +18%. F-star Therapeutics (FSTX) +16%. Enservco (ENSV) +16%. Aquestive Therapeutics (AQST) +16% receives FDA fast track...

The U.S. FDA has granted Fast Track designation to Aquestive Therapeutics' (NASDAQ:AQST) AQST-109, its epinephrine-based candidate for the treatment of severe allergic reactions. Shares are up 14% in premarket trading. AQST-109 is different from other epinephrine products in that it...